AAAAAA

   
Results: 1-21 |
Results: 21
CLINICAL-RESULTS OF A PHARMACODYNAMICALLY-BASED STRATEGY FOR HIGHER DOSING OF GEMCITABINE IN PATIENTS WITH SOLID TUMORS
Authors: TOUROUTOGLOU N GRAVEL D RABER MN PLUNKETT W ABBRUZZESE JL
Citation: N. Touroutoglou et al., CLINICAL-RESULTS OF A PHARMACODYNAMICALLY-BASED STRATEGY FOR HIGHER DOSING OF GEMCITABINE IN PATIENTS WITH SOLID TUMORS, Annals of oncology, 9(9), 1998, pp. 1003-1008
DETECTION OF PRIMARY BREAST-CANCER PRESENTING AS METASTATIC CARCINOMAOF UNKNOWN PRIMARY ORIGIN BY IN-111-PENTETREOTIDE SCAN
Authors: LENZI R KIM EE RABER MN ABBRUZZESE JL
Citation: R. Lenzi et al., DETECTION OF PRIMARY BREAST-CANCER PRESENTING AS METASTATIC CARCINOMAOF UNKNOWN PRIMARY ORIGIN BY IN-111-PENTETREOTIDE SCAN, Annals of oncology, 9(2), 1998, pp. 213-216
UNKNOWN PRIMARY TUMORS METASTATIC TO LIVER
Authors: AYOUB JP HESS KR ABBRUZZESE MC LENZI R RABER MN ABBRUZZESE JL
Citation: Jp. Ayoub et al., UNKNOWN PRIMARY TUMORS METASTATIC TO LIVER, Journal of clinical oncology, 16(6), 1998, pp. 2105-2112
POORLY DIFFERENTIATED CARCINOMA AND POORLY DIFFERENTIATED ADENOCARCINOMA OF UNKNOWN ORIGIN - FAVORABLE SUBSETS OF PATIENTS WITH UNKNOWN-PRIMARY CARCINOMA
Authors: LENZI R HESS KR ABBRUZZESE MC RABER MN ORDONEZ NG ABBRUZZESE JL
Citation: R. Lenzi et al., POORLY DIFFERENTIATED CARCINOMA AND POORLY DIFFERENTIATED ADENOCARCINOMA OF UNKNOWN ORIGIN - FAVORABLE SUBSETS OF PATIENTS WITH UNKNOWN-PRIMARY CARCINOMA, Journal of clinical oncology, 15(5), 1997, pp. 2056-2066
ARE TIME OR INTENSITY FACTORS IMPORTANT TO THE DEFINITION OF METASTASES OF UNKNOWN ORIGIN
Authors: ABBRUZZESE JL ABBRUZZESE MC LENZI R RABER MN HESS KR
Citation: Jl. Abbruzzese et al., ARE TIME OR INTENSITY FACTORS IMPORTANT TO THE DEFINITION OF METASTASES OF UNKNOWN ORIGIN, Journal of the National Cancer Institute, 88(7), 1996, pp. 462-463
PHASE-I CLINICAL AND PLASMA AND CELLULAR PHARMACOLOGICAL STUDY OF TOPOTECAN WITHOUT AND WITH GRANULOCYTE-COLONY-STIMULATING FACTOR
Authors: ABBRUZZESE JL MADDEN T SUGARMAN SM ELLIS AL LOUGHLIN S HESS KR NEWMAN RA ZWELLING LA RABER MN
Citation: Jl. Abbruzzese et al., PHASE-I CLINICAL AND PLASMA AND CELLULAR PHARMACOLOGICAL STUDY OF TOPOTECAN WITHOUT AND WITH GRANULOCYTE-COLONY-STIMULATING FACTOR, Clinical cancer research, 2(9), 1996, pp. 1489-1497
MEDICAL ONCOLOGY FOR THE GENERAL INTERNAL-MEDICINE TRAINEE
Authors: RABER MN MORTIMER JE WILLIAMS SP
Citation: Mn. Raber et al., MEDICAL ONCOLOGY FOR THE GENERAL INTERNAL-MEDICINE TRAINEE, Journal of clinical oncology, 14(3), 1996, pp. 1040-1041
PHASE-II STUDY OF TOPOTECAN IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY
Authors: PEREZSOLER R FOSSELLA FV GLISSON BS LEE JS MURPHY WK SHIN DM KEMP BL LEE JJ KANE J ROBINSON RA LIPPMAN SM KURIE JM HUBER MH RABER MN HONG WK
Citation: R. Perezsoler et al., PHASE-II STUDY OF TOPOTECAN IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY, Journal of clinical oncology, 14(2), 1996, pp. 503-513
DESIGN AND RESULTS OF PHASE-I CANCER CLINICAL-TRIALS - 3-YEAR EXPERIENCE AT MD-ANDERSON-CANCER-CENTER
Authors: SMITH TL LEE JJ KANTARJIAN HM LEGHA SS RABER MN
Citation: Tl. Smith et al., DESIGN AND RESULTS OF PHASE-I CANCER CLINICAL-TRIALS - 3-YEAR EXPERIENCE AT MD-ANDERSON-CANCER-CENTER, Journal of clinical oncology, 14(1), 1996, pp. 287-295
PHASE I-II STURDY - TRICIRIBINE (TRICYCLIC NUCLEOSIDE PHOSPHATE) FOR METASTATIC BREAST-CANCER
Authors: HOFFMAN K HOLMES FA FRASCHINI G ESPARZA L FRYE D RABER MN NEWMAN RA HORTOBAGYI GN
Citation: K. Hoffman et al., PHASE I-II STURDY - TRICIRIBINE (TRICYCLIC NUCLEOSIDE PHOSPHATE) FOR METASTATIC BREAST-CANCER, Cancer chemotherapy and pharmacology, 37(3), 1996, pp. 254-258
A PILOT-STUDY OF PACLITAXEL IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC UNKNOWN PRIMARY CARCINOMAS
Authors: LENZI R RABER MN SCHMIDT SB ABBRUZZESE JL
Citation: R. Lenzi et al., A PILOT-STUDY OF PACLITAXEL IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC UNKNOWN PRIMARY CARCINOMAS, Oncology Reports, 2(6), 1995, pp. 1127-1128
PHASE-I AND PHASE-II TRIALS OF A LABORATORY-DERIVED SYNERGISTIC COMBINATION OF CISPLATIN AND 2'-DEOXY-5-AZACYTIDINE
Authors: LENZI R RABER MN GRAVEL D FROST P ABBRUZZESE JL
Citation: R. Lenzi et al., PHASE-I AND PHASE-II TRIALS OF A LABORATORY-DERIVED SYNERGISTIC COMBINATION OF CISPLATIN AND 2'-DEOXY-5-AZACYTIDINE, International journal of oncology, 6(2), 1995, pp. 447-450
ANALYSIS OF A DIAGNOSTIC STRATEGY FOR PATIENTS WITH SUSPECTED TUMORS OF UNKNOWN ORIGIN
Authors: ABBRUZZESE JL ABBRUZZESE MC LENZI R HESS KR RABER MN
Citation: Jl. Abbruzzese et al., ANALYSIS OF A DIAGNOSTIC STRATEGY FOR PATIENTS WITH SUSPECTED TUMORS OF UNKNOWN ORIGIN, Journal of clinical oncology, 13(8), 1995, pp. 2094-2103
PHASE-I EVALUATION OF ALL-TRANS-RETINOIC ACID WITH AND WITHOUT KETOCONAZOLE IN ADULTS WITH SOLID TUMORS
Authors: LEE JS NEWMAN RA LIPPMAN SM FOSSELLA FV CALAYAG M RABER MN KRAKOFF IH HONG WK
Citation: Js. Lee et al., PHASE-I EVALUATION OF ALL-TRANS-RETINOIC ACID WITH AND WITHOUT KETOCONAZOLE IN ADULTS WITH SOLID TUMORS, Journal of clinical oncology, 13(6), 1995, pp. 1501-1508
UNKNOWN PRIMARY-CARCINOMA - NATURAL-HISTORY AND PROGNOSTIC FACTORS IN657 CONSECUTIVE PATIENTS
Authors: ABBRUZZESE JL ABBRUZZESE MC HESS KR RABER MN LENZI R FROST P
Citation: Jl. Abbruzzese et al., UNKNOWN PRIMARY-CARCINOMA - NATURAL-HISTORY AND PROGNOSTIC FACTORS IN657 CONSECUTIVE PATIENTS, Journal of clinical oncology, 12(6), 1994, pp. 1272-1280
PHASE-II CLINICAL-TRIAL OF DIDEMNIN-B IN PREVIOUSLY TREATED SMALL-CELL LUNG-CANCER
Authors: SHIN DM HOLOYE PY FORMAN A WINN R PEREZSOLER R DAKHIL S ROSENTHAL J RABER MN HONG WK
Citation: Dm. Shin et al., PHASE-II CLINICAL-TRIAL OF DIDEMNIN-B IN PREVIOUSLY TREATED SMALL-CELL LUNG-CANCER, Investigational new drugs, 12(3), 1994, pp. 243-249
PHASE-II STUDY OF CISPLATIN, 5-FLUOROURACIL AND FOLINIC ACID IN PATIENTS WITH CARCINOMA OF UNKNOWN PRIMARY ORIGIN
Authors: LENZI R RABER MN FROST P SCHMIDT S ABBRUZZESE JL
Citation: R. Lenzi et al., PHASE-II STUDY OF CISPLATIN, 5-FLUOROURACIL AND FOLINIC ACID IN PATIENTS WITH CARCINOMA OF UNKNOWN PRIMARY ORIGIN, European journal of cancer, 29A(11), 1993, pp. 1634-1634
PHASE-I EVALUATION OF ALL-TRANS-RETINOIC ACID IN ADULTS WITH SOLID TUMORS
Authors: LEE JS NEWMAN RA LIPPMAN SM HUBER MH MINOR T RABER MN KRAKOFF IH HONG WK
Citation: Js. Lee et al., PHASE-I EVALUATION OF ALL-TRANS-RETINOIC ACID IN ADULTS WITH SOLID TUMORS, Journal of clinical oncology, 11(5), 1993, pp. 959-966
THE TAXOIDS - PACLITAXEL (TAXOL(R)) AND DOCETAXEL (TAXOTERE(R))
Authors: PAZDUR R KUDELKA AP KAVANAGH JJ COHEN PR RABER MN
Citation: R. Pazdur et al., THE TAXOIDS - PACLITAXEL (TAXOL(R)) AND DOCETAXEL (TAXOTERE(R)), Cancer treatment reviews, 19(4), 1993, pp. 351-386
CLINICAL-PHARMACOLOGY OF MOYLOXYMETHYL-4-FORMYL-14-OXA-1,11-DIAZATETRACYCLO (7.4.1.0(2,7).0(10,12)) TETRADECA-2,4,6-TRIEN-6,9-DIYL DIACETATE (FK-973)
Authors: HO DH PAZDUR R BROWN NS COVINGTON WP RABER MN KRAKOFF IH
Citation: Dh. Ho et al., CLINICAL-PHARMACOLOGY OF MOYLOXYMETHYL-4-FORMYL-14-OXA-1,11-DIAZATETRACYCLO (7.4.1.0(2,7).0(10,12)) TETRADECA-2,4,6-TRIEN-6,9-DIYL DIACETATE (FK-973), Anticancer research, 13(2), 1993, pp. 343-346
THE BIOLOGY OF UNKNOWN PRIMARY TUMORS
Authors: ABBRUZZESE JL LENZI R RABER MN PATHAK S FROST P
Citation: Jl. Abbruzzese et al., THE BIOLOGY OF UNKNOWN PRIMARY TUMORS, Seminars in oncology, 20(3), 1993, pp. 238-243
Risultati: 1-21 |